JP2024528503A5 - - Google Patents
Info
- Publication number
- JP2024528503A5 JP2024528503A5 JP2023579696A JP2023579696A JP2024528503A5 JP 2024528503 A5 JP2024528503 A5 JP 2024528503A5 JP 2023579696 A JP2023579696 A JP 2023579696A JP 2023579696 A JP2023579696 A JP 2023579696A JP 2024528503 A5 JP2024528503 A5 JP 2024528503A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- dsrna agent
- chain
- nucleotide
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163216119P | 2021-06-29 | 2021-06-29 | |
| US63/216,119 | 2021-06-29 | ||
| US202263353953P | 2022-06-21 | 2022-06-21 | |
| US63/353,953 | 2022-06-21 | ||
| PCT/US2022/035561 WO2023278607A1 (en) | 2021-06-29 | 2022-06-29 | Leucine-rich repeat kinase 2 (lrrk2) irna agent compositions and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024528503A JP2024528503A (ja) | 2024-07-30 |
| JP2024528503A5 true JP2024528503A5 (enExample) | 2025-07-07 |
Family
ID=84692073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023579696A Pending JP2024528503A (ja) | 2021-06-29 | 2022-06-29 | ロイシンリッチリピートキナーゼ２（ＬＲＲＫ２）ｉＲＮＡ剤組成物およびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240301426A1 (enExample) |
| EP (1) | EP4363588A4 (enExample) |
| JP (1) | JP2024528503A (enExample) |
| KR (1) | KR20240033237A (enExample) |
| AU (1) | AU2022303358A1 (enExample) |
| BR (1) | BR112023027446A2 (enExample) |
| CA (1) | CA3225740A1 (enExample) |
| CL (3) | CL2023003984A1 (enExample) |
| CO (1) | CO2023018579A2 (enExample) |
| IL (1) | IL309548A (enExample) |
| MX (1) | MX2024000065A (enExample) |
| TW (1) | TW202317149A (enExample) |
| WO (1) | WO2023278607A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121729491A (zh) * | 2023-05-12 | 2026-03-24 | 阿尔尼拉姆制药公司 | 单链环寡核苷酸 |
| CN121712891A (zh) * | 2023-06-20 | 2026-03-20 | 阿达尔克斯制药有限公司 | Lrrk2调节组合物及其使用方法 |
| AU2024353921A1 (en) | 2023-09-27 | 2026-04-16 | Neuro3 Therapeutics (Suzhou) Ltd. | Novel sirna constructs, therapeutics, and modifications |
| CN120082552A (zh) * | 2023-12-01 | 2025-06-03 | 艾码生物科技(南京)有限公司 | 初级-miRNA及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007124096A2 (en) * | 2006-04-21 | 2007-11-01 | The Trustees Of Columbia University In The City Of New York | Lrrk2 regulaton of neuronal process morphology |
| GB201105137D0 (en) * | 2011-03-28 | 2011-05-11 | Isis Innovation | Therapeutic molecules for use in the suppression of Parkinson's disease |
| US9840703B2 (en) * | 2013-01-11 | 2017-12-12 | Children's Medical Center Corporation | Methods and compositions for the production of siRNAs |
| TWI833770B (zh) * | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | 用於減少 lrrk2 表現之化合物及方法 |
| EP3769768A1 (en) * | 2019-07-23 | 2021-01-27 | Consejo Superior de Investigaciones Cientificas (CSIC) | Compounds useful for the treatment of parkinson s disease |
-
2022
- 2022-06-29 KR KR1020247003234A patent/KR20240033237A/ko active Pending
- 2022-06-29 US US18/575,157 patent/US20240301426A1/en active Pending
- 2022-06-29 CA CA3225740A patent/CA3225740A1/en active Pending
- 2022-06-29 EP EP22834164.0A patent/EP4363588A4/en active Pending
- 2022-06-29 TW TW111124391A patent/TW202317149A/zh unknown
- 2022-06-29 WO PCT/US2022/035561 patent/WO2023278607A1/en not_active Ceased
- 2022-06-29 AU AU2022303358A patent/AU2022303358A1/en active Pending
- 2022-06-29 MX MX2024000065A patent/MX2024000065A/es unknown
- 2022-06-29 JP JP2023579696A patent/JP2024528503A/ja active Pending
- 2022-06-29 BR BR112023027446A patent/BR112023027446A2/pt unknown
- 2022-06-29 IL IL309548A patent/IL309548A/en unknown
-
2023
- 2023-12-28 CO CONC2023/0018579A patent/CO2023018579A2/es unknown
- 2023-12-29 CL CL2023003984A patent/CL2023003984A1/es unknown
-
2025
- 2025-01-20 CL CL2025000168A patent/CL2025000168A1/es unknown
- 2025-10-28 CL CL2025003326A patent/CL2025003326A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7805386B2 (ja) | Ｌｐａ発現を阻害するための組成物及び方法 | |
| CN113164509B (zh) | 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法 | |
| TWI680767B (zh) | 用於增強的細胞攝取之化合物及方法 | |
| TWI880645B (zh) | 抑制lpa之基因表現之組合物及方法 | |
| CN110268060B (zh) | α-1抗胰蛋白酶(AAT)RNAi物质、包含AAT RNAi物质的组合物和使用方法 | |
| TWI727963B (zh) | 甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物及其治療或預防ＴＴＲ相關疾病之使用方法 | |
| IL265410A (en) | Preparations and methods for inhibiting the expression of alas1 gene | |
| TW201642874A (zh) | 抑制因子ｘｉｉ基因表現之組合物及方法 | |
| JP2023523993A5 (enExample) | ||
| JP2022501057A (ja) | トランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物及びＴＴＲ関連眼疾患を治療又は予防するためのその使用方法 | |
| JP2024536811A5 (enExample) | ||
| JP2024508896A5 (enExample) | ||
| CN120699970A (zh) | 用于抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法 | |
| JP2023511434A5 (enExample) | ||
| JP2024522068A5 (enExample) | ||
| JP2023544413A5 (enExample) | ||
| JP2024509783A5 (enExample) | ||
| BR112021012516A2 (pt) | Composições e métodos para inibir a expressão de hmgb1 | |
| JP2024538859A5 (enExample) | ||
| IL294728A (en) | lrrk2 RNA material preparations and methods of using them | |
| JP2024528701A5 (enExample) | ||
| CN120118909B (zh) | 靶向调控LPA基因表达的siRNA双链体及其在预防和治疗心脑血管相关疾病中的用途 | |
| CN117187242A (zh) | 一种siRNA及其缀合物 | |
| WO2025223537A1 (zh) | 一种dsRNA、其应用及制备方法 | |
| WO2022143531A1 (zh) | 一种核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途 |